---
title: "Castle Biosciences COO Kristen Oelschlager sells 8,586 shares for $209,041.2"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291841016.md"
description: "Castle Biosciences COO Kristen M. Oelschlager sold 8,586 common shares on July 1, 2026. The transaction involved selling 8,186 shares at $24.40 and 400 shares at $24.78 per share, totaling $209,041.20. Following the sale, her directly held stake decreased to 21,874 shares."
datetime: "2026-07-06T20:25:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291841016.md)
  - [en](https://longbridge.com/en/news/291841016.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291841016.md)
---

# Castle Biosciences COO Kristen Oelschlager sells 8,586 shares for $209,041.2

-   Castle Biosciences COO Kristen M. Oelschlager reported selling 8,586 common shares on July 1, 2026. \* Sales priced at USD 24.4 per share for 8,186 shares, USD 24.78 per share for 400 shares. \* Directly held stake fell to 21,874 shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-047286), on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CSTL.US](https://longbridge.com/en/quote/CSTL.US.md)

## Related News & Research

- [Castle Biosciences CEO Derek Maetzold disposes of $202,507 in common shares](https://longbridge.com/en/news/294253874.md)
- [Castle Biosciences beats Q2 revenue estimates, hikes forecast](https://longbridge.com/en/news/294409597.md)
- [Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/293836863.md)
- [CSTL: Q2 2026 revenues up 20% YoY to $103.5M, driven by TissueCypher growth; net loss $2.1M](https://longbridge.com/en/news/294410258.md)
- [SciBase CEO Pia Renaudin to step down as board launches successor search](https://longbridge.com/en/news/294022472.md)